• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

利用监督分子动力学技术解决游离脂肪酸受体 1(FFAR1)的激活问题。

Addressing free fatty acid receptor 1 (FFAR1) activation using supervised molecular dynamics.

机构信息

School of Life Sciences, University of Essex, Wivenhoe Park, Colchester, CO4 3SQ, UK.

Centre for Sport, Exercise and Life Sciences, Coventry University, Alison Gingell Building, Coventry, CV1 5FB, UK.

出版信息

J Comput Aided Mol Des. 2020 Nov;34(11):1181-1193. doi: 10.1007/s10822-020-00338-6. Epub 2020 Aug 27.

DOI:10.1007/s10822-020-00338-6
PMID:32851580
Abstract

The free fatty acid receptor 1 (FFAR1, formerly GPR40), is a potential G protein-coupled receptor (GPCR) target for the treatment of type 2 diabetes mellitus (T2DM), as it enhances glucose-dependent insulin secretion upon activation by endogenous long-chain free fatty acids. The presence of two allosterically communicating binding sites and the lack of the conserved GPCR structural motifs challenge the general knowledge of its activation mechanism. To date, four X-ray crystal structures are available for computer-aided drug design. In this study, we employed molecular dynamics (MD) and supervised molecular dynamics (SuMD) to deliver insights into the (un)binding mechanism of the agonist MK-8666, and the allosteric communications between the two experimentally determined FFAR1 binding sites. We found that FFAR1 extracellular loop 2 (ECL2) mediates the binding of the partial agonist MK-8666. Moreover, simulations showed that the agonists MK-8666 and AP8 are reciprocally stabilized and that AP8 influences MK-8666 unbinding from FFAR1.

摘要

游离脂肪酸受体 1(FFAR1,以前称为 GPR40)是治疗 2 型糖尿病(T2DM)的潜在 G 蛋白偶联受体(GPCR)靶点,因为它在被内源性长链游离脂肪酸激活时增强葡萄糖依赖性胰岛素分泌。两个变构通讯结合位点的存在以及缺乏保守的 GPCR 结构基序挑战了其激活机制的一般知识。迄今为止,已有四个 X 射线晶体结构可用于计算机辅助药物设计。在这项研究中,我们采用分子动力学(MD)和监督分子动力学(SuMD)来深入了解激动剂 MK-8666的(非)结合机制,以及两个实验确定的 FFAR1 结合位点之间的变构通讯。我们发现 FFAR1 细胞外环 2(ECL2)介导部分激动剂 MK-8666 的结合。此外,模拟表明激动剂 MK-8666 和 AP8 是相互稳定的,并且 AP8 影响 MK-8666 从 FFAR1 上的非结合。

相似文献

1
Addressing free fatty acid receptor 1 (FFAR1) activation using supervised molecular dynamics.利用监督分子动力学技术解决游离脂肪酸受体 1(FFAR1)的激活问题。
J Comput Aided Mol Des. 2020 Nov;34(11):1181-1193. doi: 10.1007/s10822-020-00338-6. Epub 2020 Aug 27.
2
Computational Insights into Molecular Activation and Positive Cooperative Mechanisms of FFAR1 Modulators.计算洞察 FFAR1 调节剂的分子激活和正协同作用机制。
J Chem Inf Model. 2020 Jun 22;60(6):3214-3230. doi: 10.1021/acs.jcim.0c00030. Epub 2020 May 8.
3
Recent Updates on Free Fatty Acid Receptor 1 (GPR-40) Agonists for the Treatment of Type 2 Diabetes Mellitus.用于治疗2型糖尿病的游离脂肪酸受体1(GPR - 40)激动剂的最新进展
Mini Rev Med Chem. 2021;21(4):426-470. doi: 10.2174/1389557520666201023141326.
4
Molecular dynamics-guided discovery of an ago-allosteric modulator for GPR40/FFAR1.基于分子动力学的 GPR40/FFAR1 前别构调节剂的发现
Proc Natl Acad Sci U S A. 2019 Apr 2;116(14):7123-7128. doi: 10.1073/pnas.1811066116. Epub 2019 Mar 14.
5
Molecular mechanism of fatty acid activation of FFAR1.脂肪酸激活 FFAR1 的分子机制。
Proc Natl Acad Sci U S A. 2023 May 30;120(22):e2219569120. doi: 10.1073/pnas.2219569120. Epub 2023 May 22.
6
Structural basis for the cooperative allosteric activation of the free fatty acid receptor GPR40.游离脂肪酸受体 GPR40 协同变构激活的结构基础。
Nat Struct Mol Biol. 2017 Jul;24(7):570-577. doi: 10.1038/nsmb.3417. Epub 2017 Jun 5.
7
A novel antidiabetic drug, fasiglifam/TAK-875, acts as an ago-allosteric modulator of FFAR1.一种新型抗糖尿病药物法格列净/TAK-875,作为游离脂肪酸受体1(FFAR1)的正向变构调节剂发挥作用。
PLoS One. 2013 Oct 10;8(10):e76280. doi: 10.1371/journal.pone.0076280. eCollection 2013.
8
Homology modeling and explicit membrane molecular dynamics simulation to delineate the mode of binding of thiazolidinediones into FFAR1 and the mechanism of receptor activation.同源建模和显式膜分子动力学模拟以阐明噻唑烷二酮类药物与游离脂肪酸受体1(FFAR1)的结合模式及受体激活机制。
Bioorg Med Chem Lett. 2014 Nov 15;24(22):5330-6. doi: 10.1016/j.bmcl.2014.07.043. Epub 2014 Aug 7.
9
Screening of a novel free fatty acid receptor 1 (FFAR1) agonist peptide by phage display and machine learning based-amino acid substitution.通过噬菌体展示和基于机器学习的氨基酸取代筛选新型游离脂肪酸受体 1(FFAR1)激动肽。
Biochem Biophys Res Commun. 2021 Apr 23;550:177-183. doi: 10.1016/j.bbrc.2021.02.142. Epub 2021 Mar 9.
10
Identification and pharmacological characterization of multiple allosteric binding sites on the free fatty acid 1 receptor.鉴定游离脂肪酸 1 受体上的多个变构结合位点并对其进行药理学特征分析。
Mol Pharmacol. 2012 Nov;82(5):843-59. doi: 10.1124/mol.112.079640. Epub 2012 Aug 2.

引用本文的文献

1
Hidden GPCR structural transitions addressed by multiple walker supervised molecular dynamics (mwSuMD).通过多步行者监督分子动力学(mwSuMD)解决的隐藏GPCR结构转变。
Elife. 2025 Apr 30;13:RP96513. doi: 10.7554/eLife.96513.
2
Influence of the Water Model on the Structure and Interactions of the GPR40 Protein with the Lipid Membrane and the Solvent: Rigid versus Flexible Water Models.水模型对 GPR40 蛋白与脂质膜和溶剂的结构和相互作用的影响:刚性水模型与柔性水模型。
J Chem Theory Comput. 2024 Jul 23;20(14):6369-6387. doi: 10.1021/acs.jctc.4c00571. Epub 2024 Jul 11.
3
Intermolecular Interactions in G Protein-Coupled Receptor Allosteric Sites at the Membrane Interface from Molecular Dynamics Simulations and Quantum Chemical Calculations.
从分子动力学模拟和量子化学计算看跨膜 G 蛋白偶联受体变构位点的分子间相互作用。
J Chem Inf Model. 2022 Oct 10;62(19):4736-4747. doi: 10.1021/acs.jcim.2c00788. Epub 2022 Sep 30.
4
Exploring Ligand Binding to Calcitonin Gene-Related Peptide Receptors.探索配体与降钙素基因相关肽受体的结合
Front Mol Biosci. 2021 Aug 26;8:720561. doi: 10.3389/fmolb.2021.720561. eCollection 2021.
5
Deciphering the Agonist Binding Mechanism to the Adenosine A1 Receptor.解析激动剂与腺苷A1受体的结合机制。
ACS Pharmacol Transl Sci. 2021 Jan 21;4(1):314-326. doi: 10.1021/acsptsci.0c00195. eCollection 2021 Feb 12.
6
Supervised molecular dynamics for exploring the druggability of the SARS-CoV-2 spike protein.用于探索严重急性呼吸综合征冠状病毒2(SARS-CoV-2)刺突蛋白成药潜力的监督式分子动力学
J Comput Aided Mol Des. 2021 Feb;35(2):195-207. doi: 10.1007/s10822-020-00356-4. Epub 2020 Oct 26.